Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed Incorporated, a biopharmaceutical company focused on serious rare diseases, will present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 18, 2022, at 10:00 a.m. ET. The fireside chat will be available for live viewing on the company’s investor relations website and archived for 30 days post-event. Insmed’s first product targets chronic lung disease, with ongoing research into therapies for neutrophil-mediated inflammatory diseases and rare pulmonary conditions. The company is based in Bridgewater, New Jersey.
Insmed Incorporated announced the granting of inducement awards to 10 new employees as part of their recruitment strategy. Each employee received options to purchase a total of 74,410 shares of common stock at an exercise price of $23.71, aligning with the market closing price on February 1, 2022. The options have a 10-year term with a four-year vesting schedule. Insmed focuses on transforming lives through treatments for serious and rare diseases, and it is advancing a pipeline targeting unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) will announce its fourth quarter and full year 2021 financial results on February 17, 2022. Management will also provide a business and pipeline update during a conference call from 8:00 to 9:30 a.m. ET. Interested parties can join by calling specified numbers or via webcast on the company's website. A replay of the call will be available for a month. Insmed's mission is to improve lives with therapies for serious diseases, and it has a robust pipeline addressing unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:45 p.m. ET. The event will be available via live webcast on the company's website, with an archived version accessible for 30 days post-event. Insmed is focused on transforming the lives of patients with serious and rare diseases, notably with its first commercial product targeting a chronic lung disease and an expanding pipeline for unmet needs.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to six new employees, totaling 43,610 stock options exercisable at $26.69 per share. These options come with a ten-year term and a four-year vesting schedule, with 25% vesting after one year and the remainder vesting semi-annually thereafter. This move, compliant with NASDAQ Listing Rule 5635(c)(4), aims to attract talent into the company. Insmed focuses on treating serious and rare diseases, with an approved therapy for a chronic lung disease and a pipeline of investigational therapies.
Insmed has announced the grant of inducement awards to 15 new employees, approved by its Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 52,180 shares at an exercise price of $31.05, the closing price as of November 1, 2021. The options have a ten-year term and will vest over four years, with the first 25% vesting after one year, followed by 12.5% every six months. Insmed aims to improve the lives of patients with serious and rare diseases and continues expanding its pipeline of therapies.
Insmed Incorporated (Nasdaq: INSM) announced its participation in three upcoming virtual investor conferences aimed at discussing the company's developments in biopharmaceuticals. On November 9, 2021, at 10:30 a.m. ET, Insmed will join the Credit Suisse 30th Annual Virtual Healthcare Conference. This will be followed by the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 8:40 a.m. ET, and the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 8:00 a.m. ET. All events will be webcast live and archived for 30 days.
Summary not available.
Insmed Incorporated (Nasdaq: INSM) reported Q3 2021 revenue of $46.8 million, up from $43.6 million in Q3 2020. The company experienced a GAAP net loss of $112.7 million or $0.96 per share, widening from a loss of $63.7 million or $0.63 per share year-over-year. Key developments include strong initial uptake of ARIKAYCE in Japan and ongoing clinical trials for brensocatib and TPIP. Insmed ended the quarter with $846.6 million in cash and cash equivalents, positioning it well for future investments and growth.
Insmed Incorporated (Nasdaq:INSM) will release its third quarter 2021 financial results on October 28, 2021. A conference call will follow at 8:30 a.m. ET to discuss the results and offer a business update. Participants can join via phone or through a live webcast on the company's website. Insmed focuses on rare and serious diseases, with its first product being a therapy approved in multiple regions, including the US, Europe, and Japan. The company is also developing investigational therapies in high-need areas.